A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease

The purposes of this study are:

• to determine the safety and tolerability of multiple doses of A-831 at various doses
• to determine how multiple doses of A-831 are distributed through the bloodstream
• to determine if A-831 reduces the amount of Hepatitis C virus in the blood

Inclusion Criteria:

• Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical
• Volunteers who have given their written informed consent to participate in the study
• Volunteers who are willing and able to comply with the protocol and study procedures
• Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)

Exclusion Criteria:

• Voulnteers with concurrent medical conditions or taking concurrent medications